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Obesity has been postulated to increase the risk of colorectal cancer by mechanisms involving
insulin resistance and the metabolic syndrome. We examined the associations of body mass index
(BMI), waist circumference, the metabolic syndrome, metabolic obesity phenotypes and
homeostasis model-insulin resistance (HOMA-IR—a marker of insulin resistance) with risk of
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colorectal cancer in over 21,000 women in the Women’s Health Initiative CVD Biomarkers
subcohort. Women were cross-classified by BMI (18.5–<25.0, 25.0–<30.0 and ≥30.0 kg/m2) and
presence of the metabolic syndrome into 6 phenotypes: metabolically healthy normal weight
(MHNW), metabolically unhealthy normal weight (MUNW), metabolically healthy overweight
(MHOW), metabolically unhealthy overweight (MUOW), metabolically healthy obese (MHO) and
metabolically unhealthy obese (MUO). Neither BMI nor presence of the metabolic syndrome was
associated with risk of colorectal cancer, whereas waist circumference showed a robust positive
association. Relative to the MHNW phenotype, the MUNW phenotype was associated with
increased risk, whereas no other phenotype showed an association. Furthermore, HOMA-IR was
not associated with increased risk. Overall, our results do not support a direct role of metabolic
dysregulation in the development of colorectal cancer; however, they do suggest that higher waist
circumference is a risk factor, possibly reflecting the effects of increased levels of cytokines and
hormones in visceral abdominal fat on colorectal carcinogenesis.

Author Manuscript
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Obesity is associated with increased risk of colorectal cancer.1–6 Both higher levels of body
mass index (BMI, kg/m2) and other measures of adiposity, such as waist circumference, are
risk factors for the disease,1–6 although both obesity measures show weaker associations in
women compared to men.5,6 Insulin resistance and hyperinsulinemia are frequently present
in obese individuals and have been posited to play a role in colorectal cancer.7 In this regard,
relatively high circulating insulin and glucose levels have been associated with increased
colorectal cancer risk.8–10 Insulin resistance is one component of the metabolic syndrome,
which includes hyperlipidemia and hypertension as well.11 In an analysis conducted in a
subcohort of the Women’s Health Initiative,12 presence of the metabolic syndrome was
associated with increased risk of colorectal cancer in postmenopausal women (HR 2.15,
95% CI 1.30–3.53) and colon cancer (HR 2.28, 95% CI 1.31–3.98). A meta-analysis13
reported that presence of the metabolic syndrome was associated with increased risk
colorectal cancer in both men and women.

Author Manuscript

To date, few studies have examined the association of metabolically defined body size
phenotypes with risk of colorectal cancer.14,15 In a nested case–control study within the
European Prospective Investigation into Cancer and Nutrition (EPIC),14 compared to normal
weight individuals without hyperinsulinemia (indicated by C-peptide level), both normal
weight individuals (BMI < 25 kg/m2) and overweight individuals (BMI ≥25.0 kg/m2) with
hyperinsulinemia were at increased risk of colorectal cancer. In contrast, among those
without hyperinsulinemia, overweight individuals were not at increased risk compared to
normal weight individuals. Generally similar results were seen when waist circumference
was used to assess adiposity instead of BMI. In an analysis restricted to normal weight
women in the Women’s Health Initiative,15 metabolically unhealthy normal weight women
were at increased risk of colorectal cancer compared to metabolically healthy normal weight
women.
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Here we examine the association of 6 obesity phenotypes, defined at baseline by
combinations of body weight and metabolic health, as well as homeostasis model
assessment-insulin resistance (HOMA-IR), a marker of insulin resistance, with risk of
colorectal cancer in the CVD biomarkers cohort of 24,210 participants in the Women’s
Health Initiative study.

Methods

Author Manuscript

The Women’s Health Initiative is a large, multicenter study designed to improve our
understanding of the determinants of major chronic diseases in postmenopausal women. It is
composed of a clinical trial component (CT, n = 68,132) and an observational study
component (OS, n = 93,676).16 The CT component included four randomized controlled
intervention studies: hormone therapy (two trials), low-fat dietary modification and calcium
+ vitamin D supplementation. Women between the ages of 50 and 79 and representing the
major racial/ethnic groups were recruited from the general population at 40 clinical centers
throughout the US between 1993 and 1998. Details of the study design and reliability of the
baseline measures have been published.16,17
The CVD biomarkers subsample
Individuals who had baseline measurements of fasting serum glucose and insulin and other
clinical parameters that were made in various sub-studies within WHI were assembled into
the CVD biomarkers subsample (n = 25,446). Some sub-studies entailed selecting a random
sample; others selected participants based on specific age and ethnicity/race criteria within
the hormone therapy trials; another sub-study was a nested case–control study within the
hormone therapy trials with random sampling of controls (Fig. 1).

Author Manuscript

Follow-up and ascertainment of outcomes
Clinical outcomes (including new cancer diagnoses) were updated semiannually in the CT
and annually in the OS using in-person, mailed or telephone questionnaires. Self-reports of
malignancy were verified by central review of medical records and pathology reports by
trained physician adjudicators.18
Covariates

Author Manuscript

At study entry, self-administered questionnaires were used to collect information on
demographics, medical and reproductive history, family history of cancer, and lifestyle
factors, including smoking history, alcohol consumption, dietary habits, and recreational
physical activity. All participants had their weight, height, waist and hip circumference
measured by trained staff at baseline. Weight was measured to the nearest 0.1 kg, and height
to the nearest 0.1 cm. Waist circumference was measured with a tape measure at the
narrowest part of the torso between the participant’s ribs and iliac crest. Hip circumference
was measured at the site of maximum extension of the buttocks. BMI was computed as
weight in kilograms divided by the square of height in meters. Two blood pressure
measurements were obtained ≥30 sec apart, and the average of the 2 measurements was used
in the analysis. Questions about physical activity at baseline referred to a woman’s usual
pattern of activity, including walking and recreational physical activity. A variable “current
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Kabat et al.

Page 4

Author Manuscript

total leisure-time physical activity” (MET-hr/week) was computed by multiplying the
number of hours per week of leisure-time physical activity by the metabolic equivalent
(MET) value of the activity and summing over all types of activities.19
Assays for glucose, HDL-C and triglycerides

Author Manuscript

Blood was obtained after at least 8 hr of fasting for 99.8% of participants in the subsample.
The specimens were centrifuged, and serum and plasma were frozen at − 70°C and shipped
on dry ice to a central processing facility, where they were stored at − 80°C. HDL-C was
measured in serum using the HDLC Plus 3rd Generation Direct Method (Roche) on the
Roche Modular P Chemistry Analyzer. Triglycerides were measured in serum using
Triglyceride GB reagent (Roche) on the Roche Modular P Chemistry Analyzer. In the vast
majority of women (n = 22,314, 88%), glucose was measured in serum using the Glucoquant Glucose/hexokinase reagent (Roche Diagnostics, Indianapolis, IN 46250) on the
Roche Modular P Chemistry analyzer (Roche Diagnostics Corporation); in the remainder,
serum glucose was determined by the hexokinase method on the Hitachi 747 (Boehringer
Mannheim Diagnostics, Indianapolis, IN). Insulin was determined using the Sandwich
Immunoassay (Roche Diagnostics) on Roche Elecsys 2010 Analyzer.
Definition of the metabolic syndrome

Author Manuscript

We used the National Cholesterol Education Program (NCEP) Adult Treatment Panel III
(ATP III) definition of the metabolic syndrome: having ≥3 of the 5 following criteria: waist
circumference ≥88 cm, triglycerides ≥150 mg/dl, HDL-C <50 mg/dl, glucose ≥100 mg/dl
and systolic/diastolic blood pressure ≥130/85 mmHg or treatment for hypertension.11 To
assess the relative contributions of adiposity and metabolic factors to the risk of colorectal
cancer, we also examined the metabolic obesity phenotypes using an alternative definition
which excluded waist circumference from the ATP III definition (presence of the metabolic
syndrome defined as ≥2 of the 4 remaining components). Furthermore, because the
metabolic syndrome is a constellation of heterogenous factors, we additionally computed
homeostasis model assessment-insulin resistance (HOMA-IR), a measure of insulin
resistance, using the formula (fasting glucose (mg/dl) × fasting insulin (mg/dl)/405).20
Exclusions

Author Manuscript

For the purposes of the present analysis, baseline BMI and components of the metabolic
syndrome were available for 23,900 (99%) of the 24,210 women in the subsample. We
excluded women with diabetes reported at baseline (n = 2,346, 9.7%), women with BMI
<18.5 (n = 310, 1.3%), women missing waist circumference measurements (n = 59, 0.2%)
and women with a history of colorectal cancer (n = 387, 1.6%). Women with diabetes
reported at enrollment were excluded for two reasons: (i) our focus is on the influence of the
metabolic syndrome, which is a precursor of diabetes and (ii) treatment of diabetes may
influence the clinical factors (i.e., components of the metabolic syndrome). After exclusions
(some of which were overlapping), 21,170 women were available for analysis (88% of
women with information on the metabolic syndrome and BMI), among whom, as of
September 30, 2016, 474 incident invasive colorectal cancer cases had been ascertained. Of
these, 397 were classified as colon cancer, 47 as rectal cancer and 5 as both colon and rectal
cancer. For 25 cases, information on subsite was not available. We compared the distribution
Int J Cancer. Author manuscript; available in PMC 2019 November 25.
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of sociodemographic and lifestyle variables in excluded women to the distribution in the
study population. Most factors, including age, BMI, WC, smoking, caloric intake, education
and hormone therapy did not differ between excluded and included subjects. However,
alcohol intake, physical activity and the proportion of whites were lower in the excluded
subjects.
Statistical analysis

Author Manuscript

Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95%
confidence intervals (CI) for the associations of interest. The outcome was time to diagnosis
of colorectal cancer. Participants who had not developed the disease by the end of follow-up,
who had died or who withdrew from the study before the end of follow-up were censored.
Cases contributed person-time to the study from their date of enrollment until the date of
diagnosis, and noncases (participants who were censored) contributed person-time from
their date of enrollment until the date of withdrawal from the study, the date of death, or the
end of follow-up (September 30, 2016), whichever came first. We examined both ageadjusted and fully-adjusted models, which included colorectal cancer risk factors as well as
other potential confounding variables. As the results differed little, we present the fully
adjusted results. We also adjusted for red meat intake; however, this made no difference, and
meat was not included in the final model.

Author Manuscript

We examined the association of categories of BMI (18.5– <25.0, normal weight; 25.0–
<30.0, overweight; ≥30.0 kg/m2, obese) and waist circumference (<83.0, 83.0–<95.0 and
≥95.0 cm) and of presence of the metabolic syndrome, separately and with mutual
adjustment, with risk of colorectal cancer. We then estimated risk after cross-classifying
women by categories of BMI and presence of the metabolic syndrome simultaneously,
yielding six groups: metabolically healthy/normal weight (MHNW); metabolically
unhealthy/normal weight (MUNW); metabolically healthy/overweight (MHOW);
metabolically unhealthy/overweight (MUOW); metabolically healthy/obese (MHO);
metabolically unhealthy/obese (MUO).
Because the metabolic syndrome is a composite, which additionally includes components
other than those related to hyperglycemia/hyperinsulinemia (i.e., lipids and hypertension),
we also examined the associations of other components of the metabolic syndrome
(hypertension, HDL-C and triglycerides) and quartiles of HOMA-IR with risk of colorectal
cancer, with and without adjustment for BMI and waist circumference.

Author Manuscript

Tests for linear trend were performed by assigning the median value to each category,
modeling the variable as a continuous variable, and using the Wald test for linear trend (p <
0.05).
We conducted four sensitivity analyses: (i) we excluded the first 3 years of follow-up to
address the possibility of reverse causation (effects of subclinical cancer on body weight and
metabolic status). (ii) Because waist circumference is strongly correlated with BMI, we
repeated the analyses after excluding waist circumference from the definition of the
metabolic syndrome and defining presence of the syndrome as ≥2 of the four remaining
components. (iii) Because participation in the intervention arm of the dietary clinical trials
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could affect the results, we repeated the main analyses excluding women who were in these
interventions. (iv) Because the distribution of clinical variables (including glucose and
insulin) differed in the 4 studies making up the subcohort, as an alternative to using cutpoints derived from the total study population, we reanalyzed the data for the association of
glucose, HLD-C, triglycerides and HOMA-IR, with colorectal cancer using the original cutpoints from each study and “stacking” the different studies.
We tested the proportional hazards assumption using PROC LIFETEST (SAS Institute,
Cary, NC). Formal tests for nonproportional hazards and the log–log survival plots did not
indicate any marked deviation from the proportional hazards assumption. All analyses were
performed in SAS 9.4 (SAS Institute, Cary, NC). All p values are two-sided.

Results
Author Manuscript

The metabolic obesity phenotypes showed differences by demographic and behavioral
characteristics (Table 1). Within BMI categories, compared to metabolically healthy women,
metabolically unhealthy women tended to be older and to have fewer years of education, and
were more likely to be white and to be current smokers. Both alcohol intake and MET-hr/
week of physical activity showed decreasing trends from MHNW to MUO.
Neither body mass index nor presence of the metabolic syndrome was associated with
colorectal cancer risk—in age-adjusted models, when considered separately with adjustment
for other covariates, or when mutually adjusted (Table 2). The results were similar in women
who had never used hormone therapy (data not shown).

Author Manuscript

In the age-adjusted model and the model adjusted for covariates other than the metabolic
syndrome, waist circumference was positively associated with colorectal cancer risk (HR for
highest tertile 1.34, 95% CI 1.04–1.72), whereas the metabolic syndrome was not associated
with altered risk (Table 3). When waist circumference and presence of the metabolic
syndrome were mutually adjusted, the HR for waist circumference was slightly attenuated,
and that for the metabolic syndrome was further weakened. Similar results were seen when
the analysis was restricted to never users of hormone therapy (data not shown).
When waist circumference and BMI were entered in the same model with metabolic
syndrome, HRs for the 2nd and 3rd tertile of waist circumference were 1.40, 95% CI
1.031.89 and 2.29, 95% CI 1.57–3.35, respectively, p for trend <0.0001, and HRs for BMI
25.0–30.0 and for BMI ≥30.0 kg/ m2 were 0.69, 95% CI 0.51–0.93 and 0.48, 95% CI 0.33–
0.70, respectively, p for trend = 0.01. Presence of the metabolic syndrome continued to show
no association (data not shown).

Author Manuscript

Compared to metabolically healthy normal weight women (reference group), only
metabolically unhealthy normal weight women had an elevated HR (1.65, 95% CI 0.99–
2.74) (Table 4). No other group showed any suggestion of an elevated risk (in spite of the
larger numbers compared to the MUNW group). When the first 3 years of follow-up were
excluded to address the possibility of reverse causation, the results were similar, although
the confidence intervals were wider due to the decreased sample size. When examined
individually, with the exception of waist circumference, none of the components of the
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metabolic syndrome (glucose, HDL-C, triglycerides or hypertension) showed any
association with colorectal cancer (data not shown). In the sensitivity analysis excluding
women in the intervention arms of the 2 dietary clinical trials, the association of BMI and
WC with CRC were unchanged, whereas the association of MUNW with CRC was
strengthened (HR 1.83, 95% CI 1.04–3.21).
HOMA-IR, a measure of insulin resistance, showed no association with colorectal cancer;
however, in the same model, waist circumference showed a robust positive association
(Table 5). The pattern of associations was unchanged when the analysis was restricted to
women who had never used hormone therapy (data not shown).

Author Manuscript

In the analyses restricted to colon cancer, the HR for presence of the metabolic syndrome
was 1.22, 95% CI 0.98–1.52 and the HRs for colon cancer associated with the different
phenotypes, relative to the MHNW phenotype, were MUNW 1.79, 95% CI 1.02–3.12;
MHOW 0.87, 95% CI 0.63–1.21; MUOW 1.26, 95% CI 0.87–1.83; MHO 0.93, 95% CI
0.64–1.36; MUO 1.12, 95% CI 0.80–1.56. The association of waist circumference with
colon cancer was strengthened (HR for highest vs. lowest tertile 1.45, 95% CI 1.10–1.91).
In the sensitivity analysis in which waist circumference was not included as a component of
the metabolic syndrome, the HR for MUNW relative to MHNW was attenuated (1.35, 95%
CI 0.91–2.02). None of the other metabolic phenotypes was associated with risk (Supporting
Information, Table). In the sensitivity analysis using the original study-specific cutpoints, the
results were unchanged.

Discussion
Author Manuscript

In this prospective study of postmenopausal women, BMI was not associated with risk of
colorectal cancer, whereas waist circumference was positively associated with risk. Of 5
metabolic obesity phenotypes, relative to metabolically healthy normal weight women, only
metabolically unhealthy normal weight women showed a borderline increased risk.
Individual components of the metabolic syndrome showed no association. Furthermore,
HOMA-IR was not associated with risk. Overall, our results suggest that that abdominal
adiposity is a robust risk factor for colorectal cancer in women, whereas both presence of the
metabolic syndrome and insulin resistance showed no overall association and only a possible
association in normal weight women.

Author Manuscript

Two previous studies suggest that metabolically unhealthy normal weight individuals are at
elevated risk of colorectal cancer compared to metabolically healthy normal weight
individuals,14,15 and one of these14 indicated that metabolically unhealthy overweight
individuals were at increased risk compared to metabolically healthy normal weight and to
metabolically healthy overweight individuals. Metabolically healthy overweight individuals
were not at increased risk compared to metabolically healthy normal weight individuals.14
In contrast to the EPIC study,14 our analysis was not limited by comparing normal weight
versus overweight/obese, but included 3 levels of BMI: normal weight, overweight and
obese, thereby permitting us to examine the full range of adiposity. Our results are consistent
with those of Murphy et al.14 regarding MUNW versus MHNW; however, we found little
Int J Cancer. Author manuscript; available in PMC 2019 November 25.
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indication that either the MUOW or MUO phenotypes were at increased risk relative to
MHNW women.

Author Manuscript
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Differences between our results and those of Liang et al.,15 which also made use of the CVD
biomarkers subcohort of the Women’s Health Initiative, can be explained by the different
analytic approaches taken in the two analyses. Liang et al. restricted attention to normal
weight women in WHI, whereas we included normal weight, overweight and obese women.
Further, Liang et al. excluded women with a history of any cancer (except nonmelanoma
skin cancer), whereas we only excluded women with a history of colorectal cancer. On the
other hand, we excluded women with a history of diabetes, whereas Liang et al. did not. The
number of cases among normal weight women in the two analyses were 114 (Liang et al.)
and 134 (this study). Our approach permitted us to examine waist circumference, BMI and
HOMA-IR in the total study population (474 cases and 20,696 noncases). Thus, our finding
of a positive association of waist circumference with risk is not in conflict with Liang et al.’s
finding of no association of waist circumference with risk in normal weight women. As the
number of cases among normal weight women is not large (n = 114), it is possible that
differences in the selection of subjects and covariates included in the multivariable analyses
in the two analyses may account for differences in which factors showed significant
associations. For example, Liang et al. reported a positive association of fasting glucose (no/
yes) with colorectal cancer: HR 1.70, 95% CI 1.12–2.58. The corresponding HR in our study
was 1.48, 95% CI 0.92–2.37). Liang et al. found no association of waist circumference with
risk. In our analysis of normal weight women, tertiles of waist circumference were also not
significantly associated with risk, due it appears to the limited sample size: 1.25, 95% CI
0.73–2.15 and 2.86, 95% CI 0.69–11.83, for the second and third tertile, respectively. When
treated as a dichotomous variable (<88 cm, ≥88 cm), waist circumference was also not
significant (HR 1.18, 95% CI 0.48–2.91). Our results were not altered when women with a
history of cancer were excluded from the analysis. Finally, the association of waist
circumference with colorectal cancer risk we observed in the WHI CVD biomarkers
subcohort is consistent with the association observed in the total WHI cohort.4,21

Author Manuscript

The hypothesis that obesity and related metabolic alterations are associated with risk of
colorectal cancer has gained widespread support in recent years.22,23 A meta-analysis
summarizing the evidence from cohort studies13 indicated that the metabolic syndrome was
associated with an elevated risk of colorectal cancer both in men (RR 1.33, 95% CI 1.18–
1.50) and in women (RR 1.41, 95% CI 1.18–1.70). The risk associated with dysglycemia
was similar to that of the full metabolic syndrome, suggesting that elevated glucose may
account for the association with the syndrome. And an analysis of the EPIC cohort24 showed
that the association of the metabolic syndrome with colon cancer was largely accounted for
by abdominal obesity and abnormal glucose metabolism, suggesting that excess fat storage
and consequent hyperglycemia and hyperinsulinemia are important factors.
Our findings provide little support for the hypothesis that metabolic dysregulation is directly
associated with increased risk of colorectal cancer. Presence of the metabolic syndrome
showed only a modest and imprecise association with colorectal cancer, and, except for
waist circumference, the individual components of metabolic syndrome were not associated
with risk. HOMA-IR was also not associated with risk; and, of the metabolic phenotypes,
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only metabolically unhealthy normal weight women were at increased risk compared to
metabolically healthy normal weight women. However, in view of the small number of
colorectal cancer cases in this category, this association could be due to chance. On the other
hand, waist circumference was significantly associated with increased risk. Our results
suggest that that centrally located adipose tissue may be an important risk factor for
colorectal cancer in women. This association could be driven by visceral (or intraabdominal)
fat, as visceral fat is metabolically more active than subcutaneous abdominal fat and secretes
larger amounts of cytokines and hormones compared to subcutaneous fat.24 However, we did
not have a direct measure of different abdominal adipose tissue depots.

Author Manuscript
Author Manuscript

Strengths of this study include its large sample size, the central adjudication of all colorectal
cancer diagnoses, the availability of fasting blood samples on virtually all participants,
measurements of all components of the metabolic syndrome, as well as insulin and HOMAIR, and anthropometric measures. Additionally, we carried out sensitivity analyses, first,
excluding the first 3 years of follow-up to address the possibility of reverse causality,
second, excluding waist circumference from the definition of the metabolic syndrome, since
waist circumference is strongly correlated with BMI, which is used to define the metabolic
obesity phenotypes. An additional sensitivity analysis excluded women in the intervention
arms of the dietary clinical trials, which did not affect the results. Limitations include the
small numbers of cases in the MUNW phenotype group and the lack of information on
change in metabolic phenotype and adiposity over time. Also, misclassification of the study
factors would likely attenuate the observed associations, whereas misclassification of
covariates, such as physical activity, could weaken the correction for confounding. However,
the main finding, regarding waist, was robust and was consistent in different analyses.
Finally, the Women’s Health Initiative is not a representative sample and, therefore, our
results are not generalizable to all postmenopausal women. Nevertheless, analyses within the
cohort should have validity.
In conclusion, in this study, waist circumference was positively associated with risk of
colorectal cancer, whereas BMI was not. Compared to metabolically healthy normal weight
women, only metabolically unhealthy normal weight women had a borderline elevated risk;
no other phenotypes showed any indication of increased risk. Overall, presence of the
metabolic syndrome showed little association with risk, and HOMA-IR was not associated
with risk. Our results provide little support for a direct association of metabolic
dysregulation with risk of colorectal cancer. The association of waist circumference with
increased risk, may be mediated by the effects of increased production of cytokines and
hormones in visceral adipose tissue.

Author Manuscript
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Refer to Web version on PubMed Central for supplementary material.
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What’s new?
Obesity is associated with increased risk of colorectal cancer, as is a high level of insulin
in the bloodstream. To tease out the relationship between body weight, metabolic health,
and colorectal cancer risk, these authors examined data on six different body profiles.
Neither BMI nor metabolic syndrome appeared to impact colorectal cancer risk. Waist
circumference, however, significantly boosted the risk, possibly due to the increased
cytokines and hormones present in fat that accumulates around the waist.
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Figure 1.

Make-up of WHI CVD biomarker sample.
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230

244

No

Yes

MetS

p for trend

9,938

10,758

8,159

7,504

5,033

Noncases
(n = 20,696)

1.19

1.00

0.76

0.94

0.85

1.00

1

HR

0.99–1.44

Ref.

0.75–1.18

0.68–1.07

Ref.

95% CI

1.16

1.00

0.33

0.86

0.84

1.00

2

HR

0.95–1.41

Ref.

0.66–1.12

0.65–1.09
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95% CI

1.19

1.00

0.18

0.81

0.81

1.00

3

HR

0.97–1.47

Ref.

0.61–1.06

0.63–1.06

Ref.

95% CI

In addition to the above covariates, waist circumference and MetS are mutually adjusted.

3

HRs for waist circumference and MetS are from separate models, adjusted for age (continuous), smoking status (never, former, current), pack-years of smoking (continuous), alcohol intake (drinks/week—
continuous), physical activity (MET-hr/week), aspirin intake, dietary calcium intake, dietary folate intake, caloric intake, oral contraceptives (never, ever), hormone therapy (never, ever), parous/nulliparous,
family history of colorectal cancer in first-degree relative (no, yes), education (less than high school grad, high school grad/some college, college grad, postcollege), ethnicity (white, black, other) and
allocation to the OS or specific arm of clinical trials.

2

Age-adjusted HR.

1
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25.0–<30.0
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131

18.5–<25.0

≥30.0
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(n=474)

BMI (kg/m2)

Separate and mutually adjusted associations of body mass index and presence of the metabolic syndrome with colorectal cancer, Women’s Health
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230
244

No

Yes

MetS

p for trend

9,938

10,758

6,407

7,038

7,369

Noncases
(n = 20,028)

1.09

1.00

0.003

1.39
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In addition to the above covariates, waist circumference and MetS are mutually adjusted.

3

HRs for waist circumference and MetS are from separate models, adjusted for age (continuous), smoking status (never, former, current), pack-years of smoking (continuous), alcohol intake (drinks/week—
continuous), physical activity (MET-hr/week), aspirin intake, dietary calcium intake, dietary folate intake, caloric intake, oral contraceptives (never, ever), hormone therapy (never, ever), parous/nulliparous,
family history of colorectal cancer in first-degree relative (no, yes), education (less than high school grad, high school grad/some college, college grad, postcollege), ethnicity (white, black, other) and
allocation to the OS or specific arm of clinical trials.
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Age-adjusted HR.

1

151

83.0–<95.0
171

154
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Cases
(n = 474)

Waist circumference
(cm)

Separate and mutually adjusted associations of waist circumference and presence of the metabolic syndrome with colorectal cancer, Women’s Health
Initiative CVD biomarkers subcohort
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N cases

N noncases

99
64
70
110

MUOW

MHO

MUO

4,821

3,338

2,388

5,116

542

4,491

2

0.97

0.85

1.11

0.80

1.65

1.00

HR

0.72–1.32

0.60–1.20

0.79–1.57
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4,711
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0.94
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0.67–1.33

0.57–1.25

0.76–1.63

0.56–1.10

0.92–2.89
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Definition includes waist circumference.
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Adjusted for age (continuous), smoking status (never, former, current), pack-years of smoking (continuous), alcohol intake (drinks/week – continuous), physical activity (MET-hrs/wk), aspirin intake,
dietary calcium intake, dietary folate intake, caloric intake, oral contraceptives (never, ever), hormone therapy (never, ever), parous/nulliparous, family history of colorectal cancer in first-degree relative (no,
yes), education (less than high school grad, high school grad/some college, college grad, post-college), ethnicity (white, black, other), allocation to the OS or specific arm of clinical trials.

2

1

Abbreviations: MHNW, metabolically healthy normal weight; MUNW, metabolically unhealthy normal weight; MHOW, metabolically healthy overweight; MUOW, metabolically unhealthy overweight;
MHO, metabolically healthy obese; MUO, metabolically unhealthy obese.
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Metabolic phenotypes
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Association of quartiles of HOMA-IR and anthropometric measures with colorectal cancer, Women’s Health
Initiative CVD biomarkers subcohort
N cases

N
noncases

HR

95% CI

1

125

5,517

1.00

Ref.

2

117

5,436

1.02

0.77–1.34

3

120

5,192

0.84

0.62–1.14

4

93

3,992

0.88

0.63–1.24

1

2,3

HOMA-IR

p trend

0.39

Waist circumference
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WC <83.0 cm

145

7,121

1.00

Ref.

WC 83.0-<95.0 cm

143

6,805

1.09

0.84–1.40

WC >95.0 cm

167

6,211

1.52

1.15–2.01

p trend

0.002

1

Adjusted for age (continuous), smoking status (never, former, current), pack-years of smoking (continuous), alcohol intake (drinks/week continuous), physical activity (MET-hr/week), aspirin intake, dietary calcium intake, dietary folate intake, caloric intake, oral contraceptives (never,
ever), hormone therapy (never, ever), parous/nulliparous, family history of colorectal cancer in first-degree relative (no, yes), education (less than
high school grad, high school grad/some college, college grad, postcollege), ethnicity (white, black, other), allocation to the OS or specific arm of
clinical trials and mutually adjusted (HOMA-IR and WC).

2

Quartiles: <7.3, 7.3–<11.4, 11.4–<18.7, ≥18.7.

3

Twenty-one cases and 682 noncases missing HOMA-IR measurement.
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